Pacer Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Pacer Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6,999	Closed	-$447K	–	3586
2025 Q1	$447K	Sell	6,999 -13,056	-65%	-$1.37M	﹤0.01%	1505
2024 Q4	$2.44M	Sell	20,055 -932	-4%	-$114K	0.01%	893
2024 Q3	$2.62M	Buy	20,987 +5,989	+40%	+$828K	0.01%	850
2024 Q2	$2.37M	Buy	14,998 +14,654	+4,260%	+$1.88M	0.01%	843
2024 Q1	$44.5K	Buy	+344	New	+$42.1K	﹤0.01%	3214
2021 Q2	–	Sell	-895	Closed	-$67K	–	1545
2021 Q1	$67K	Buy	895 +66	+8%	+$6.09K	﹤0.01%	1393
2020 Q4	$141K	Buy	829 +168	+25%	+$24.9K	﹤0.01%	1292
2020 Q3	$93K	Buy	+661	New	+$100K	﹤0.01%	1259
2018 Q4	–	Sell	-2,580	Closed	-$417K	–	973
2018 Q3	$417K	Buy	+2,580	New	+$353K	0.02%	900
2018 Q1	–	Sell	-2,600	Closed	-$145K	–	1123
2017 Q4	$145K	Buy	+2,600	New	+$138K	0.01%	927

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Pacer Advisors's SRPT Position: Q2 2025 in Review

Pacer Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 6,999 shares — an estimated $447K sold.

Pacer Advisors first reported a position in SRPT in Q4 2017 and held it in 10 quarters. The position peaked at $2.62M in Q3 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

Pacer Advisors reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
Pacer Advisors sold 6,999 Sarepta Therapeutics shares in Q2 2025, an estimated $447K.
Pacer Advisors first reported a position in Sarepta Therapeutics in Q4 2017 and held it in 10 quarters.
Pacer Advisors's Sarepta Therapeutics position peaked at $2.62M in Q3 2024.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Pacer Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.